Crossing the 40-year-old target IL-2 to return to the hot track

Article source: Medical Rubik's Cube Info

In the first 20 years of the 21st century, PD-1 is undoubtedly the most successful target in the field of immunity so far, and the accompanying tumor immunotherapy has become one of the current hot tracks

(Starting in 2017, as the commercialization potential of PD-1 has been gradually confirmed, related IL-2/IL-2R product transactions have gradually become hot)

Source of information: NextPharma Global New Drug Database

In fact, IL-2 is already a relatively mature anti-cancer target.

Reference: Spolski R, et al.

As the most competitive country among PD-1 players in the world, similarly, IL-2 also has many players in the layout

Information source: NextTarget target database

For new companies entering the market, in the field of independent research and development, Hengrui Medicine currently has two IL-2 drugs under development, namely SHR-1916 and RS2102.

Like Hengrui, Cinda Biotech has adopted an independent research and development model

In the pipeline integration area, we have to look at how Junshi bought and bought.

Source of information: NextPharma Global New Drug Database

Not only at home, Junshi also chose a cooperative enterprise abroad

In less than a month, Junshi has successively obtained the development license rights for three IL-2 drugs, which can be described as vigorous and resolute

Finally, looking back and closer, Junshi’s three transactions have a total of expenditure: 306.

Note: The original text has been deleted